BPC-157

Nobody knows reliably, because it has not been studied properly in people. The FDA’s adverse event database holds three reports with injected BPC-157: injection-site redness and swelling for 9 days, shortness of breath that led to an emergency room visit, and darkening of the skin and gums with a BPC-157 and TB-500 product sold for “research purposes only”. Because the product held two peptides, the FDA said it could not assess whether BPC-157 caused it. Long-term effects in people are unknown. In animal injection studies, BPC-157 was linked to changes in blood clotting and liver tests, and the FDA warns of immune reactions and impurities in injected peptides.

None have been shown in a controlled human trial. In rats and other animals, BPC-157 was reported to speed healing of tendon, ligament, muscle, bone and gut injuries. In people there are only small, mostly uncontrolled reports: less knee pain in 11 of 12 people in a clinic chart review, and symptom relief in 10 of 12 women with interstitial cystitis. The FDA reviewed BPC-157 for ulcerative colitis and concluded the data do not support that use. A 2026 review also discusses the placebo effect, amplified by social media, as a factor in how well peptides seem to work.

Only small, uncontrolled human reports have been published. Registered trials have not reported yet. A phase 1 trial of an oral BPC-157 tablet was registered in 2015, and its status is unknown with nothing published. In 2026, a phase 2 trial in China began testing BPC-157 injected under the skin against placebo in 120 people with an MRI-confirmed hamstring strain, with primary completion estimated for February 2027. A phase 1 trial at the University of Arkansas in 30 people after rotator cuff surgery is set to start in January 2027. None of the published human reports gave BPC-157 by mouth or under the skin; BPC-157 oral vs injection explains what is and isn’t known about each route.

BPC-157 is not FDA-approved, and the FDA says no country has approved a BPC-157 product. The FDA treats BPC-157 acetate and BPC-157 free base as different ingredients and reviewed both. As of April 2026 its nominations had been withdrawn from the FDA’s Category 2 safety-risk list, which does not mean it was found safe. In July 2026 FDA staff recommended against allowing pharmacies to compound it; the advisory committee narrowly voted the other way. That vote is not binding. The FDA would have to publish a proposed rule first, and as of October 16, 2026 it had not.

Yes, it is banned. WADA’s 2026 Prohibited List names BPC-157 under S0, non-approved substances, banned in and out of competition. Anti-doping scientists have studied how BPC-157 breaks down in human plasma in order to screen for it. If you are tested in sport, check with your anti-doping organization before using any unapproved substance.

In people, it is unknown. After an IV dose in animals, its half-life was 5.3 minutes in dogs and 15.2 minutes in rats, likely because enzymes in blood and tissue break it down. When injected into muscle, about 14% to 19% reached the bloodstream in rats and 45% to 51% in dogs. There are no human data on how much is absorbed by mouth, under the skin, in the nose or through the skin, and in the two enema studies BPC-157 was not found in the blood.